Yasuda, Mina
Tobino, Kazunori
Harada, Norihiro
Ooi, Ryunosuke
Sueyasu, Takuto
Nishizawa, Saori
Munechika, Miyuki
Yoshimine, Kohei
Ko, Yuki
Yoshimatsu, Yuki
Tsuruno, Kosuke
Ide, Hiromi
Takahashi, Kazuhisa
Article History
Received: 29 September 2023
Accepted: 16 January 2024
First Online: 3 February 2024
Declarations
:
: The present study was reviewed and approved by Iizuka Hospital Ethics Committee (AIH-17120). Written informed consent was.obtained from each patient before their participation in the study. This study was registered in the UMIN Clinical Trial Registry (UMIN000034263)(ExternalRef removed).
: Not applicable.
: NH reports personal fees from AstraZeneca and GlaxoSmithKline, and grants from Kyorin, outside the submitted work. KT reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chugai, Eli Lilly, Kyorin, MSD, Nobelpharma, Novartis, Ono, Pfizer, Teijin, and grants from Astellas, GlaxoSmithKline, Kyowa Hakko Kirin, MiZ, Mochida, Nipro, Nippon Shinyaku, Taiho, Toyama Chemical, Tsumura, Sanofi, Shionogi, Torii, and personal fees from Bristol-Myers, Eisai, Meiji Seika, Mitsubishi Tanabe, Otsuka, Parexel, Sumitomo Dainippon, outside the submitted work. The rest of the authors have no conflict of interest.